NCT01792479

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: BIND Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	BIND-014

Timeline

• Start date: 2013-04-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2013-02-15
• Last updated: 2016-04-15

Locations

17 sites across 2 countries: United States, Russia